US009511065B2

(12) **United States Patent**
Sackler

(10) **Patent No.: US 9,511,065 B2**
(45) **Date of Patent: *Dec. 6, 2016**

(54) **PHARMACEUTICAL FORMULATION CONTAINING IRRITANT**

(71) Applicant: **Purdue Pharma L.P.**, Stamford, CT (US)

(72) Inventor: **Richard Sackler**, Greenwich, CT (US)

(73) Assignee: **Purdue Pharma L.P.**, Stamford, CT (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/842,406**

(22) Filed: **Sep. 1, 2015**

(65) **Prior Publication Data**

US 2015/0366861 A1 Dec. 24, 2015

Related U.S. Application Data

(63) Continuation of application No. 14/148,909, filed on Jan. 7, 2014, now Pat. No. 9,155,717, which is a continuation of application No. 12/763,898, filed on Apr. 20, 2010, now Pat. No. 8,652,497, which is a continuation of application No. 11/525,395, filed on Sep. 22, 2006, now Pat. No. 7,727,557, which is a continuation of application No. 10/214,410, filed on Aug. 6, 2002, now Pat. No. 7,157,103.

(60) Provisional application No. 60/310,535, filed on Aug. 6, 2001.

(51) **Int. Cl.**

A61K 31/485	(2006.01)
A61K 9/20	(2006.01)
A61K 31/135	(2006.01)
A61K 31/165	(2006.01)
A61K 9/48	(2006.01)
A61K 9/16	(2006.01)
A61K 9/127	(2006.01)
A61K 9/50	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/485*** (2013.01); ***A61K 9/1611*** (2013.01); ***A61K 9/1617*** (2013.01); ***A61K 9/1635*** (2013.01); ***A61K 9/1647*** (2013.01); ***A61K 9/205*** (2013.01); ***A61K 9/2013*** (2013.01); ***A61K 9/2027*** (2013.01); ***A61K 9/2054*** (2013.01); ***A61K 9/2081*** (2013.01); ***A61K 9/4808*** (2013.01); ***A61K 9/4866*** (2013.01); ***A61K 9/5078*** (2013.01); ***A61K 31/135*** (2013.01); ***A61K 31/165*** (2013.01); *A61K 9/1272* (2013.01); *A61K 9/1694* (2013.01); *A61K 9/5026* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,980,766	A	9/1976	Shaw et al.	
4,385,057	A	5/1983	Bjork et al.	
4,769,372	A	9/1988	Kreek	
5,149,538	A	9/1992	Granger et al.	
5,376,705	A	12/1994	Leys et al.	
5,403,868	A	4/1995	Reid et al.	
5,679,650	A	10/1997	Fukunaga et al.	
5,716,625	A *	2/1998	Hahn	A61K 8/19 424/401
5,762,963	A	6/1998	Byas-Smith	
5,891,919	A	4/1999	Blum et al.	
6,228,863	B1	5/2001	Palermo et al.	
6,277,398	B1	8/2001	Caruso	
6,375,957	B1	4/2002	Kaiko et al.	
6,440,464	B1	8/2002	Hsia et al.	
6,627,635	B2	9/2003	Palermo et al.	
6,696,066	B2	2/2004	Kaiko et al.	
6,696,088	B2	2/2004	Oshlack et al.	
6,716,449	B2	4/2004	Oshlack et al.	
6,828,349	B1	12/2004	Dewey et al.	
7,141,250	B2	11/2006	Oshlack et al.	
7,144,587	B2	12/2006	Oshlack et al.	
7,157,103	B2	1/2007	Sackler	
7,332,182	B2	2/2008	Sackler	
7,658,939	B2	2/2010	Oshlack et al.	
7,682,632	B2	3/2010	Oshlack et al.	
7,718,192	B2	5/2010	Oshlack et al.	
7,727,557	B2	6/2010	Sackler	
7,842,307	B2	11/2010	Wright	
7,842,309	B2	11/2010	Oshlack et al.	
7,842,311	B2	11/2010	Oshlack et al.	
7,914,818	B2	3/2011	Oshlack et al.	
7,943,173	B2	5/2011	Oshlack et al.	

(Continued)

FOREIGN PATENT DOCUMENTS

EP	1293195	3/2003
JP	60013710	1/1985

(Continued)

OTHER PUBLICATIONS

Abstract of JP Publication No. 60013710A (Jan. 24, 1985).

(Continued)

Primary Examiner — Susan Tran

(74) *Attorney, Agent, or Firm* — Davidson, Davidson & Kappel, LLC

(57) **ABSTRACT**

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.

14 Claims, No Drawings